FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$124M
This Quarter Return
+26.38%
1 Year Return
-24.36%
3 Year Return
+1.86%
5 Year Return
+16.17%
10 Year Return
–
AUM
$288M
AUM Growth
+$288M
(+30%)
Cap. Flow
+$21.9M
Cap. Flow
% of AUM
7.61%
Top 10 Holdings %
Top 10 Hldgs %
91.85%
Holding
18
New
3
Increased
8
Reduced
4
Closed
2
Top Buys
| 1 |
Rhythm Pharmaceuticals
RYTM
|
$16.3M |
| 2 |
OPTN
OptiNose
OPTN
|
$12.4M |
| 3 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$8.63M |
| 4 |
Arbutus Biopharma
ABUS
|
$8.52M |
| 5 |
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
|
$4.99M |
Top Sells
| 1 |
uniQure
QURE
|
$20.8M |
| 2 |
Ascendis Pharma
ASND
|
$13.6M |
| 3 |
Arcus Biosciences
RCUS
|
$4.35M |
| 4 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
$2.39M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
$1.19M |
Sector Composition
| 1 | Healthcare | 89.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Insmed
INSM
$28.8B
| $42.6M | 14.52% | 1,800,587 +1,362 | +0.1% | +$32.2K |
|
|
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $33.6M | 11.47% | 851,200 | – | – |
|
|
IMMU
3
DELISTED
Immunomedics Inc
IMMU
| $29.2M | 9.94% | 1,231,543 +158,271 | +15% | +$3.75M |
|
|
MYOK
4
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $28.1M | 9.58% | 565,755 +173,800 | +44% | +$8.63M |
|
|
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
| $27.2M | 9.26% | 2,023,369 -88,500 | -4% | -$1.19M |
|
|
OPTN
6
DELISTED
OptiNose
OPTN
| $26M | 8.86% | 928,545 +444,939 | +92% | +$12.4M |
|
|
7
Rhythm Pharmaceuticals
RYTM
$6.85B
| $22.6M | 7.69% | 721,903 +521,903 | +261% | +$16.3M |
|
|
8
Arbutus Biopharma
ABUS
$711M
| $19.4M | 6.6% | 2,651,825 +1,166,580 | +79% | +$8.52M |
|
|
9
Ascendis Pharma
ASND
$11.8B
| $18M | 6.13% | 270,424 -204,995 | -43% | -$13.6M |
|
|
ALDR
10
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $17.9M | 6.09% | 1,130,919 +300,000 | +36% | +$4.74M |
|
11
Aclaris Therapeutics
ACRS
$209M
| $10.6M | 3.6% | 529,551 +100,000 | +23% | +$2M |
|
|
EIDX
12
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $4.99M | 1.7% | +245,082 | New | +$4.99M |
|
|
13
Arcus Biosciences
RCUS
$1.13B
| $3.61M | 1.23% | 295,000 -355,000 | -55% | -$4.35M |
|
|
TCDA
14
DELISTED
Tricida, Inc. Common Stock
TCDA
| $2.24M | 0.76% | +75,000 | New | +$2.24M |
|
15
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $1.64M | 0.56% | +94,477 | New | +$1.64M |
|
|
16
uniQure
QURE
$896M
| $403K | 0.14% | 10,650 -549,423 | -98% | -$20.8M |
|
17
Solid Biosciences
SLDB
$427M
| – | – | -140,332 | Closed | -$1.05M |
|
|
RARX
18
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| – | – | -450,000 | Closed | -$2.39M |
|